Sunvalley Communication

05/28/2024

Uiteindelijk wil Curaçao 10 gigawatt aan drijvend windvermogen voor zijn kust hebben.

04/24/2023

National Historic Vessel - Pirate Radio Station - 60's Side Trawler ... Ross Revenge is one of the last remaining 60's side trawlers still afloat, and home to the legendary Radio Caroline since the early 1980's. The history of Ross Revenge is documented in it's entirety through our website and havin...

04/04/2023

https://conta.cc/412KWo6

“Think of ADCs as guided missiles, in which the antibody is the cancer detector andthe cytotoxin the missile’s warhead.”

03/27/2023

Join the The Onco'Zine Brief - Affordable National Sponsorship & Advertising Opportunities Designed to Connect with 75 million Highly Engaged Listeners

https://conta.cc/40Bq1Z5

Connect with 75 million Engaged Listeners     Connect with Engaged Listeners AFFORDABLE NATIONAL SPONSORSHIP & ADVERTISING OPPORTUNITY to 75 million people Hello Peter,   The Onco’Zine Brief® is avail

03/17/2023

One month after CANCER/EVOLUTION director Maggie Jones’ 40th birthday, she was diagnosed with terminal, stage 4 lung cancer that had spread to her eye, liver...

02/07/2023

https://conta.cc/3XmmGLK

Your World ADC London, UK | Full Agenda! Greetings! With over 211 antibody-drug conjugate (ADC) clinical trials breaking ground so far throughout 2022, a plethora of positive clinical results, expansi

01/26/2023

Java Original Coffee Company to Support The Onco’Zine Brief Radio Broadcast and Podcast

Read the full press release on PRWEB/PRNEWSWIRE
http://bit.ly/3R497yZ

The Java Original Coffee Company, the home of incredible artisan roasted gourmet coffee, is committed to support the cancer research community as well as select individuals and organizations involved in the treatment of (pediatric) cancer patients.

Java Original Coffee also supports select organizations developing continued education programs for physicians and ongoing healthcare information programs for (cancer) patient and their family & friends.

The Onco’Zine Brief, a radio show and podcast about (new) research findings in cancer, cancer prevention, - diagnoses, - treatment, is one of the 13 recipients chosen by the Java Original Coffee Company to benefit from the company's 'Shop-for-a-Cause/Make a Difference' campaign.

Read the full press release on PRWEB/PRNEWSWIRE
http://bit.ly/3R497yZ

12/14/2022

News & Updates from the San Antonio Breast Cancer Symposium (SABCS), held December 6 - 10, 2022

https://conta.cc/3hj7b8p

12/07/2022

https://conta.cc/3P33fES

Imagine a world where cancer therapies kill only the cancer. Dear Peter, Imagine a world where cancer therapies kill only the cancer. Cancer is an enemy that is difficult to defeat. For more t

11/24/2022

EVANSTON, Ill. (PRWEB) November 22, 2022 -- AMUN-003, being developed by AmunBio, is a first-in-class oncolytic virus that directly kills cancer cells while simultaneously stimulating an anti-tumor immune response. In preclinical studies AMUN-003, in combination with Checkpoint Inhibitors, showed si...

11/14/2022

https://conta.cc/3hBjk8d

In early November, Actinium Pharmaceuticals reached a primary endpoint with positive results from their Phase 1 clinical trial (NCT03441048) evaluating lintuzumab-Ac225 (Actimab-A), a novel CD33 directed antibody-radiotherapy conjugate (ARC), with salvage chemotherapy regimen CLAG-M in fit patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML). These results further cemented the evidence that radiopharmaceuticals will soon be playing a key role in cancers beyond the prostate.

Discover how to use radiopharmaceuticals in conjunction with ADCs at the 4th Annual Targeted Radiopharmaceuticals Europe, the world-leading industry forum designed to overcome the most critical industry challenges facing the field today.

Click to Register for the 4th Annual Targeted Radiopharmaceuticals Summit Europe
https://adc.expert/4th_annual_targeted_radiopharmaceuticals_Europe

TRP | Targeted Radiopharmaceuticals Summit (Europe) Greetings! Extracting the most value from targeting systems in antibody-drug conjugates (ADCs) could require a mind open to the parallel field of ra

10/19/2022

The ESMO - European Society for Medical Oncology Congress is one of the most important and influential oncology meetings worldwide. This annual event was held this year in Paris, France and included clinicians, researchers, patient advocates, and healthcare industry representatives coming together from all over the world.

A recent episode The Onco’Zine Brief, includes an interview with Neil H. Ba**er, Founder/Chief Scientific Advisor of Convergent, about advances in the development of new cancer therapies and about the company’s therapeutic platform targeting cancer antigens such as prostate-specific membrane antigen (PSMA). To listen to the full discussion, click the link below:

https://lnkd.in/eQYG7zXe

09/11/2022

https://conta.cc/3BjzwCB

Download this peer reviewed article from ADC Review | Journal of Antibody-drug Conjugates Greetings! Learn more about validating protein concentrations of Antibody-Drug Conjugates by downloading the p

09/07/2022

https://conta.cc/3KKxcHZ

2nd ADC Target Selection Summit Greetings! We're excited to share with you the official program for the 2nd ADC Target Selection Summit which will be taking place in-person for the first time this yea

09/02/2022

The The Onco'Zine Brief with Peter Hofland on UK Health Radio Peter talks with Dr. Ranjit Bindra the co-founder of Modify Bio, about a new approach that redefines the rules on how to selectively kill cancer cells via direct DNA modification.

👉🏼 🎧 bit.ly/3ebfQaN

09/01/2022

CHANDLER, Ariz. (PRWEB) September 01, 2022 -- ADC Review | Journal of Antibody-drug Conjugates, a peer-reviewed journal published by Sunvalley Communication, LLC, is pleased that Bernhard Stump, Ph.D., Head of Development of Bioconjugation at Lonza in Visp, Switzerland, has joined the publication's....

06/24/2022

https://conta.cc/3OCUQXj

This year, from June 3 - 7, 2022, the annual meeting of the American Society of Clinical Oncology (ASCO) was back in person. And this year, with an estimated 38,000 oncology professionals from around the world meeting together to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field, it seemed like everything was again as usual… And, for most of us, the conference felt indeed indistinguishable compared to the last in-person conference in 2019...

But if you missed this year’s ASCO, or want to read more about new, practice-changing, developments, check out the highlights prepared by the editorial teams of Onco’Zine & ADC Review | Journal of Antibody-drug Conjugates.

https://conta.cc/3OCUQXj

A Selection of Key Presentation Highlights From the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) The 2022 ASCO Theme: Advancing Equitable Cancer Care Through Innovation ASC

06/21/2022

https://riverside.fm/?utm_campaign=campaign_1&utm_medium=affiliate&utm_source=rewardful&via=peter-hofland

06/21/2022

https://www.siteground.com/recommended?referrer_id=8055914

Our web hosting is trusted by more than 2,800,000 domains for its top speed, unmatched security, 24/7 fast, and expert support! Get started now!

03/29/2022

https://conta.cc/3IN83tv

The inaugural ADC Analytical Development Summit is taking place in Boston, MA - May 25-27, 2022.

Optimizing the end-to-end usage of cell-based and biophysical analytical methods to enhance ADC characterization, demonstrate drug potency and homogeneity to support regulatory approval, this three day meeting will offer a focused networking experience with likeminded industry peers. Follow the link for more information: https://conta.cc/3IN83tv

03/29/2022

https://conta.cc/37YtmLM

Your Programme for World ADC London, UK | 29th March - 1st April 2022 | Speaker Abstracts | With 70+ speakers sharing unparalleled insights to help bring more clinically impactful ADCs to the hands of patients sooner, this is your opportunity to reunite with the ADC community at Europe's biggest and most comprehensive antibody-drug conjugate event.... Click on the Link to Read More https://conta.cc/37YtmLM

03/09/2022

https://conta.cc/3IWckf3

The Novel Format Conjugates Summit is your opportunity to get involved and immerse yourself in the world of next-generation bioconjugates. Spanning three days, the comprehensive agenda will cover all aspects of developing an alternative format conjugate. Join the cross-disciplinary discussions to learn from other companies' approaches, network with the industry's leading bioconjugation minds, and suss out potential collaborations for next-generation ADCs and novel format conjugates.

Join your peers in April - view your registration options here, and save up to $800 if you secure your place before Friday, March 11.

02/16/2022

https://conta.cc/3uQJEjp

The 12th Annual World ADC London, UK returns between 29th March – 1st April 2022 as Europe’s longest-standing and definitive antibody-drug conjugate event

Register by Friday 18th February 2022 and save £300.

12/11/2021

Listen to this episode from The Onco'Zine Brief on Spotify. Cancer remains the second leading cause of death in the world, and numbers are on the rise. To respond to the growing need for therapeutic solutions, much research is needed. In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. tal...

11/03/2021

ALA sonodynamic therapy for GBM offers the promise of being both targeted and comprehensive. It’s targeted because it should be highly selective for fast-growing GBM tumors while barely affecting slow-growing normal cells.